Nucleis is a radiopharmaceutical company which manufacture and distribute Radiopharmaceutical
Drugs for Diagnostic and Therapy Monitoring.
The company was created in June 2017 with the transfer of the business unit (existing team,
pharmaceutical certifications, CMO contracts and dedicated manufacturing facilities) from CRC
(Cyclotron Research Centre – Liège Belgium) and benefits from over 15 years of experience.
The company core-business consists in the manufacturing of Market Authorised drugs and
Investigational Medicinal Products dedicated to PET. NUCLEIS is also a key partner for CMO activities.
NUCLEIS is the MAH (Marketing Authorisation Holder) and Manufacturer of a “FDG” (fludeoxyglucose
(18F) MA (Marketing Authorisation) granted in Belgium, The Netherlands, Luxembourg, France and
Germany. Furthermore, as part of their CMO activities, NUCLEIS is registered as Manufacturer in
several MA granted among EMA (European Medicines Agency) and in several Investigational
Medicinal Product Dossier (IMPD). NUCLEIS aims at developing constantly a wide portfolio of
diagnostics tools in order to support the emergence of innovative therapies.
Nucleis is an authorized manufacturer of GE Healthcare Radiopharmaceuticals and of Blue Earth
Diagnostics.
Nucleis maintains a strong partnership with CRC for the development of new tracers and R&D
activities (access to adapted resources and facilities).
CONTACT
GIACOMELLI FABRICE – CEO
+32 (0) 4 366 23 22
+32 (0) 498 12 71 80
fabrice.giacomelli@nucleis.eu
BARTKOWIAK PASCAL – SALES MANAGER
+32 (0) 4 366 23 22
+32 (0) 470 54 29 82
pascal.bartkowiak@nucleis.eu
